Therapeutic plasma exchange in neurological diseases: Eleven years experience at a tertiary care center in Turkey.
acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
chronic inflammatory demyelinating polyneuropathy (CIDP)
multiple sclerosis (MS)
therapeutic plasma exchange
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
10
05
2021
received:
25
03
2021
accepted:
12
06
2021
pubmed:
27
6
2021
medline:
4
3
2022
entrez:
26
6
2021
Statut:
ppublish
Résumé
Therapeutic plasma exchange (TPE) is an apheresis procedure in which plasma is separated from the blood cellular components ex vivo, allocated, and replaced with another plasma or a plasma-replacing fluid. This study aimed to define the rate of complications and determine TPE distribution in various neurological diseases. Our study is a retrospective analysis of neurologic diseases requiring TPE between 2008 and 2019 that were selected using the medical records of neurology departments and apheresis units database. We performed 1459 TPE procedures on 207 patients between 2008 and 2019. TPE Procedure is most frequently applied in patients with Myasthenia-Gravis syndrome (34.7%). The complication ratio was 1.6% from a total of 1459 TPE procedures. The most commonly specified adverse event was allergic reactions 11 (5.3%), followed by hypotension 6 (2.9%). TPE was safe and tolerable, with manageable complications in experienced hands.
Identifiants
pubmed: 34173719
doi: 10.1111/1744-9987.13703
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
465-470Informations de copyright
© 2021 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Korach J-M, Berger P, Giraud C, Le Perff-Desman C, Chillet P. Role of replacement fluids in the immediate complications of plasma exchange. Intensive Care Med. 1998;24:452-8.
Strauss RG, Ciavarella D, Gilcher RO, Kasprisin DO, Kiprov DD, Klein HG, et al. An overview of current management. J Clin Apher. 1993;8:189-94.
Braun N, Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther Apher. 1999;3:240-5.
Hehmke B, Salzsieder E, Matic GB, Winkler RE, Tiess M, Ramlow W. Immunoadsorption of immunoglobulins alters intracytoplasmic type 1 and type 2 T cell cytokine production in patients with refractory autoimmune diseases. Ther Apher. 2000;4:296-302.
Schröder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother. 2009;9:1331-9.
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher. 2019;34:171-354.
Cortese I, Chaudhry V, So Y, Cantor F, Cornblath D, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment subcommittee of the American Academy of Neurology. Neurology. 2011;76:294-300.
Hughes R, Newsom-Davis J, Perkin G, Pierce J. Controlled trial of prednisolone in acute polyneuropathy. The Lancet. 1978;312:750-3.
Yücesan C, Arslan Ö, Arat M, Yücemen N, Ayyildiz E, Ilhan O, et al. Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases. Transfus Apher Sci. 2007;36:103-7.
Gwathmey K, Balogun RA, Burns T. Neurologic indications for therapeutic plasma exchange: 2011 update. J Clin Apher. 2012;27:138-45.
Syndrome FCGoPEiGB. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987;22:753-61.
Consensus N. The utility of therapeutic plasmapheresis for neurological disorders. NIH Consensus Conference. JAMA. 1986;256:1333-7.
Rodnitzky RL, Bosch EP. Chronic long-interval plasma exchange in myasthenia gravis. Arch Neurol. 1984;41:715-7.
Korkmaz S, Medeni SS, Demirkan F, Besisik SK, Dadin SA, Cagliyan GA, et al. The Turkish experience with therapeutic plasma exchange: a national survey. Transfus Apher Sci. 2019;58:287-92.
Chhibber V, Weinstein R, editors. Evidence-based review of therapeutic plasma exchange in neurological disorders. Semin Dial, Wiley Online Library; 2012;132-9.
Kaya E, Keklik M, Şencan M, Yilmaz M, Keskin A, Kiki I, et al. Therapeutic plasma exchange in patients with neurological diseases: multicenter retrospective analysis. Transfus Apher Sci. 2013;48:349-52.
Kaynar L, Altuntas F, Aydogdu I, Turgut B, Kocyigit I, Hacıoglu SK, et al. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. Transfus Apher Sci. 2008;38:109-15.
Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007;22:270-6.
Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23:817-27.
Tombak A, Uçar MA, Akdeniz A, Yilmaz A, Kaleagası H, Sungur MA, et al. Therapeutic plasma exchange in patients with neurologic disorders: review of 63 cases. Indian J Hematol Blood Transfus. 2017;33:97-105.
Shahidi S, Memarzadeh M, Kamali M, Naini AE. Trend of indications for therapeutic plasma exchange at an Iranian university hospital. Transfus Apher Sci. 2011;44:119-22.
Henze T, Prange H, Talartschik J, Rumpf K. Complications of plasma exchange in patients with neurological diseases. Klin Wochenschr. 1990;68:1183-8.
Szczeklik W, Wawrzycka K, Włudarczyk A, Sega A, Nowak I, Seczyńska B, et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther. 2013;45:7-13.
Laird J, Douglas K, Green R. Heparin-induced thrombocytopenia type II: a rare but significant complication of plasma exchange. J Clin Apher. 2006;21:129-31.
Mateen FJ, Gastineau D. Transfusion related acute lung injury (TRALI) after plasma exchange in myasthenic crisis. Neurocrit Care. 2008;8:280-2.
Korach JM, Guillevin L, Petitpas D, Berger P, Chillet P, Group FRS. Apheresis registry in France: indications, techniques, and complications. Ther Apher. 2000;4:207-10.
Keller A, Chirnside A, Urbaniak S. Coagulation abnormalities produced by plasma exchange on the cell separator with special reference to fibrinogen and platelet levels. Br J Haematol. 1979;42:593-603.
Chirnside A, Urbaniak S, Prowse C, Keller A. Coagulation abnormalities following intensive plasma exchange on the cell separator: II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol. 1981;48:627-34.
Jagdish K, Jacob S, Varughese S, David V, Mohapatra A, Valson A, et al. Effect of double filtration plasmapheresis on various plasma components and patient safety: a prospective observational cohort study. Indian J Nephrol. 2017;27:377-83.
Pearlman E, Litty C, Edger N, Ballas S. Effect of therapeutic plasmapheresis on coagulation parameters. J Clin Apher. 1994;9:202-3.
Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;7:CD001798. https://doi.org/10.1002/14651858.CD001798.pub2.